|
|
|
|
Publications 2003
|
- Aandahl EM, Sandberg JK, Beckerman KP, Taskén K, Moretto WJ, Nixon DF (2003) CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J. Immunol. 170:2349–2355.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139:258–266.
- Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA (2003) Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. JAIDS 34:475–481.
- Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CH, Grant RM, Busch MP [for the Viral Activation Transfusion Study (VATS) Group] (2003) Absence of hepatitis B and C virus, human T-cell leukemia virus I/II, and human herpesvirus-8 activation following allogeneic red blood cell transfusion in patients with advanced HIV-1 infection. Transfusion 43:451–458.
- Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17:1925–1932.
- Chen L-f, Greene WC (2003) Regulation of distinct biological activities of the NF-kB transcription factor complex by acetylation. J. Mol. Med. 81:549–557.
- D’Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. (2003) Drug resistance mutations in HIV-1. Topics HIV Med. 11:92–96.
- Deeks SG, Grant RM, Wrin T, Paxinos E, Liegler T, Hoh R, Martin JN, Petropoulos CJ (2003) Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17:361–370.
- Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Verdin E (2003) HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18:687–698.
- García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM (2003) A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: A randomized study. AIDS 17:43–51.
- Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D’Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Jr., Reid C, Morgan GF, Winslow DL. (2003) Accuracy of the TRUGENE HIV-1 Genotyping Kit. J. Clin. Microbiol. 41:1586–1593.
- Hayden MS, Palacios EH, Grant RM. (2003) Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS 17:629–631.
- Hellerstein MK, Hoh RA, Hanley MB, Cesar D, Lee D, Neese RA, McCune JM. (2003) Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 112:956–966.
- Heltweg B, Dequiedt F, Verdin E, Jung M. (2003) Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal. Biochem. 319:42–48.
- Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA. (2003) In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Virol. 77:5846–5854.
- Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868–1877.
- Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schnoelzer M, Loret E, Cole PA, Verdin E, Ott M. (2003) Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol. Cell 12:167–176.
- Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF (2003) Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J. Virol. 77:6743–6752.
- Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E. Comparisn of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Imm. Methods 283:141–153.
- Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Jr., Reid C, Morgan GF, Winslow DL. (2003) Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA Sequencing System. J. Clin. Microbiol. 41:1594–1599.
- Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP. (2003) Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J. Acquir. Immune Defic. Syndr. 33:655–656.
- Napolitano LA, Stoddart CA, Hanley MB, Wieder E, McCune JM. (2003) Effects of IL-7 on early human thymocyte progenitor cells in vitro and in SCID-hu Thy/Liv mice. J. Immunol. 171:645–654.
- Napolitano LA (2003) Approaches to immune reconstitution in HIV infection. Top. HIV Med. 11:160–163.
- Nixon DF, Aandahl EM, Sandberg JK (2003) New observations on CD8 cell responses. AIDS 17 Suppl. 4:S61–65.
- North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11:4377–444.
- O'Mahony A, Chen L-f, Greene WC. (2003) New insights into the regulation of NF-kB: Roles for phosphorylation and acetylation of NF-kB subunits. In: Nuclear Factor kB: Regulation and Role in Disease (Beyaert R, ed) Kluwer Academic Publishers, Netherlands, pp159–176.
- Papasavvas E, Sandberg JK, Rutstein R, Moore EC, Mackiewicz A, Thiel B, Pistilli M, June RR, Jordan KA, Gross R, Maino VC, Nixon DF, Montaner LJ. (2003) Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression. J. Inf. Dis. 188:873–882.
- Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ (2003) Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 17:2337–2343.
- Pion M, Jordan A, Biancotto A, Dequiedt F, Gondois-Rey F, Rondeau S, Vigne R, Hejnar J, Verdin E, Hirsch I. (2003) Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J. Virol. 77:4025–4032.
- Sandberg JK, Bhardwaj N, Nixon DF (2003) Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Va24 NKT cell compartment. Eur. J. Immunol. 33:588–596.
- Sandberg JK, Fast NM, Jordan KA, Furlan SN, Barbour JD, Fennelly G, Dobroszycki J, Spiegel HML, Wiznia A, Rosenberg MG, Nixon DF (2003) HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J. Immunol. 170:4403–4410.
- Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF (2003) Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue (GALT) during chronic infection. J. Virol. 77:5621–5631.
- Shacklett BL, Yang O, Hausner MA, Elliot J, Hultin L, Price C, Fuerst M, Matud J, Hultin P, Cox CA, Ibarrondo J, Wong J, Nixon DF, Anton PA, Jamieson BD. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J. Immunol. Methods. 279:17–31.
- Sherman MP, de Noronha CMC, Eckstein LA, Hataye J, Mundt P, Williams SAF, Neidleman JA, Goldsmith MA, Greene WC (2003) Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J. Virol. 77:7582–7589.
- Snow JW, Abraham N, Ma MC, Pastuszak AW, Herndier BG, Goldsmith MA (2003) Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol.171:5042–5050.
- Snow JW, Abraham N, Ma MC, Bronson SK, Goldsmith MA (2003) Transgenic bcl-2 is not sufficient to rescue all hematolymphoid defects in STAT5A/5B-deficient mice. Exp. Hematol.31:1253–1258.
- Snow JW, Abraham N, Ma MC, Goldsmith MA (2003) Bone marrow transplant completely rescues hematolymphoid defects in STAT5A/5B-deficient mice. Exp. Hematol.31:1247–1252.
- Stoddart CA, Geleziunas R, Ferrell S, Linquist-Stepps V, Moreno ME, Bare C, Xu W, Yonemoto W, Bresnahan PA, McCune JM, Greene WC (2003) Human immunodeficiency virus type 1 nef-mediated downregulation of CD4 correlates with nef enhancement of viral pathogenesis J. Virol. 77:2124–2133.
- Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell.12:591–601.
- Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: Versatile regulators. Trends Genet. 19:286–293.
- Zander K, Sherman MP, Tessmer U, Bruns K, Wray V, Prechtel AT, Schubert E, Henklein P, Luban J, Neidleman J, Greene WC, Schubert U (2003) Cyclophilin A interacts with HIV-1 and is required for its functional expression. J. Biol. Chem.278:43202-43213.
|
|
|
|
|
|
